Drugs / BEBT-109
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06001671 | Oct 2020 → Mar 2023 | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06514027 | Jul 2024 → Jun 2027 expected | non-small cell lung carcinoma | BeBetter Med Inc | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06706713 | Apr 2022 → Dec 2025 overdue | non-small cell lung carcinoma | BeBetter Med Inc | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BEBT-109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06514027 ↗ |
| Action | Inhibit | “a Novel EGFR Inhibitor” NCT06001671 ↗ |
| Route | Oral | “BEBT-109 orally at an initial dose of 120 mg once daily.” NCT06001671 ↗ |
| Target | EGFR | “a Novel EGFR Inhibitor” NCT06001671 ↗ |